We are live on ! Find out more
ALPN

Alpine Immune Sciences Inc

Delisted

ALPN was delisted on the 17th of May, 2024.

24 hedge funds and large institutions have $36.7M invested in Alpine Immune Sciences Inc in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

4% more funds holding

Funds holding: 2324 (+1)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

14% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 7

39% less capital invested

Capital invested by funds: $59.9M → $36.7M (-$23.2M)

Holders
24
Holders Change
+1
Holders Change %
+4.35%
% of All Funds
0.52%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
3
Increased
6
Reduced
7
Closed
2
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
O
1
OrbiMed
New York
$15.5M
FM
2
Frazier Management
Washington
$10.8M
BI
3
BVF Inc
California
$4.85M -$289K -50,000 -4%
DM
4
Deerfield Management
New York
$1.75M -$344K -59,542 -13%
Vanguard Group
5
Vanguard Group
Pennsylvania
$853K +$472K +81,800 +68%
TM
6
Tiger Management
New York
$580K
Victory Capital Management
7
Victory Capital Management
Texas
$552K -$20.3K -3,520 -3%
HP
8
Hikari Power
Japan
$511K -$9.29K -1,609 -1%
Renaissance Technologies
9
Renaissance Technologies
New York
$447K +$60.1K +10,400 +11%
Dimensional Fund Advisors
10
Dimensional Fund Advisors
Texas
$183K +$10.7K +1,845 +4%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$157K
BlackRock
12
BlackRock
New York
$105K -$491 -85 -0.3%
Jacobs Levy Equity Management
13
Jacobs Levy Equity Management
New Jersey
$90K +$123K +21,274 New
RJA
14
Raymond James & Associates
Florida
$66K +$11K +1,897 +14%
AWCI
15
Alpine Woods Capital Investors
New York
$63K
Northern Trust
16
Northern Trust
Illinois
$44K
DS
17
DRW Securities
Illinois
$42K
LRIA
18
Leonard Rickey Investment Advisors
Washington
$42K +$57.8K +10,000 New
Morgan Stanley
19
Morgan Stanley
New York
$29K +$1.97K +341 +5%
PAM
20
Panagora Asset Management
Massachusetts
$25K -$1.51K -261 -4%
UBS Group
21
UBS Group
Switzerland
$5K +$5K +866 +329%
Wells Fargo
22
Wells Fargo
California
$2K
Royal Bank of Canada
23
Royal Bank of Canada
Ontario, Canada
$1K -$2.89K -500 -67%
BCM
24
Bridgeway Capital Management
Texas
-$245K -35,750 Closed
TRCT
25
Tower Research Capital (TRC)
New York
-$4K -633 Closed

ALPN Hedge Fund Activity: Q2 2019 in Review

24 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q2 2019, worth a combined $36.7M — down 39% from $59.9M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ALPN positions and 2 closed out — a net gain of 1 holder — while 6 added to existing stakes and 7 trimmed.

The largest buyer was Vanguard Group, adding an estimated $472K. The largest seller was Deerfield Management, cutting an estimated $344K.

  • 24 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q2 2019, up from 23 in Q1 2019.
  • Funds reported $36.7M of Alpine Immune Sciences Inc stock for Q2 2019, down 39% quarter-over-quarter.
  • 3 funds opened new Alpine Immune Sciences Inc positions in Q2 2019 and 2 closed out, a net change of +1 holder.
  • The largest Alpine Immune Sciences Inc buyer in Q2 2019 was Vanguard Group, an estimated $472K added.
  • The largest Alpine Immune Sciences Inc seller in Q2 2019 was Deerfield Management, an estimated $344K sold.

Based on aggregated 13F filings for Q2 2019.